THE SCIENCE
What the Ipamorelin research actually shows, study by study.
The receptor mechanism, the selectivity that named it, the synergy that explains the GHRH-analog pairings, and the one human trial that anchors it all.
Before the details
Here is the Ipamorelin research in one breath. It is a five-amino-acid peptide that switches on the ghrelin receptor (GHS-R1a) on the pituitary gland and makes it release a pulse of growth hormone. Its claim to fame, proven in its very first study, is selectivity: it raises growth hormone without raising the stress hormone cortisol — something the older peptides could not do. Because it works through a different doorway than growth-hormone-releasing hormone (GHRH), pairing it with a GHRH analog like CJC-1295 produces more growth hormone than either alone — the studies below show this synergy in rats, mice, and pituitary cells. In animals it reliably nudges bone growth; in the one real human trial, for slow bowels after surgery, it did not beat placebo. Everything that follows is the detail behind those sentences, each finding cited to its source.
What is ipamorelin peptide
Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — built by stripping the central Ala-Trp dipeptide out of the older peptide GHRP-1. The unusual residues (alpha-aminoisobutyric acid at position one, plus D-form naphthylalanine and phenylalanine) make it resist the enzymes that would normally chew a peptide apart. It is a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a), the same receptor the hunger hormone ghrelin uses. Functionally, it is a ghrelin mimetic that tells pituitary cells to release a pulse of growth hormone [1]. It is not an endogenous human peptide — the body does not make it — and it is classified as a research peptide, not an approved drug.
The mechanism: a ghrelin-receptor switch for growth hormone
Ipamorelin binds GHS-R1a on pituitary somatotrophs — the cells that store and release growth hormone — and activates a Gq/phospholipase-C cascade that raises intracellular calcium and triggers GH release [1]. This is a genuinely different pathway from GHRH, which works through cAMP, and that difference is the entire mechanistic basis for combining the two. The receptor is not only in the pituitary: GHS-R1a also sits on enteric and vagal neurons (where ghrelin agonism speeds gastric motility, the rationale for the ileus trial), on pancreatic islet cells (a GH-independent insulin effect), and in hypothalamic appetite circuitry (the class-level appetite signal). Downstream, GH can raise hepatic IGF-1, though short rodent studies often show GH-pulse effects — like bone growth — without a measurable IGF-1 rise [4].
The selectivity that gave it its name
In its 1998 founding characterization, Ipamorelin released GH potently across primary rat pituitary cells, anaesthetised rats, and conscious swine — with a swine ED50 of 2.3 nmol/kg, comparable to GHRP-6's 3.9 nmol/kg — yet it did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its GH ED50 [1]. That is the result that made it the first highly GH-selective growth hormone secretagogue and the reason it is still discussed three decades later. The older peptides GHRP-6 and GHRP-2 release GH well but also stimulate cortisol and prolactin; Ipamorelin separated the GH signal from those off-target axes, which is its single most-cited and most-replicated property.
Ipamorelin cjc-1295
The Ipamorelin cjc-1295 pairing is grounded in a real, repeatedly demonstrated synergy between the GHRH and GHRP pathways — not in a combination trial. In rats neutralized of endogenous GHRH and somatostatin, exogenous GHRH plus a GHRP produced GH peaks significantly greater than the sum of the two given alone [12]. The dependency runs the other way too: GHRP-6 activity in rats was sharply attenuated by GHRH antiserum or receptor blockade, proving endogenous GHRH is required for the full GH-releasing effect of a secretagogue [13]. Genetic models seal it — in GHRH-knockout mice, a GHRP alone failed to stimulate GH, while GHRH analog plus GHRP together restored growth [14], and in ovine pituitary cells the combination upregulated GH mRNA, GHS-R, GHRH-R, and Pit-1 while suppressing somatostatin receptors [15]. CJC-1295 is the GHRH-analog half of that logic; Ipamorelin is the selective GHRP half.
What is cjc-1295 ipamorelin
What is cjc-1295 ipamorelin: it is a two-peptide combination that pairs a GHRH analog (CJC-1295) with a selective ghrelin-receptor GHRP (Ipamorelin) to hit both arms of the growth-hormone control system at once. The premise is mechanistic, not clinical — GHRH and GHRP release GH by distinct, complementary pathways, and combining them produces a GH response larger than either alone [12]. This site documents pure Ipamorelin; the combination is described here only to explain the pairing's rationale and to set the record straight. No controlled human trial of the combination exists for any outcome, so its effects in people remain extrapolated from single-agent pharmacology rather than demonstrated [3].
Does cjc-1295 ipamorelin work
Does cjc-1295 ipamorelin work is a question the published record cannot answer directly, because no controlled human trial of the combination has been run. What the literature does establish is the building blocks: GHRH-plus-GHRP synergy that exceeds additive GH release in animals [12], and a confirmed requirement for GHRH tone to get full GHRP effect [13]. For Ipamorelin alone, the human picture is thin and partly negative — the single Phase 2 trial for postoperative ileus missed its endpoint [3] — while the animal data show real, dose-dependent effects on bone growth [4]. So the honest reading is: the mechanism is sound and reproducible in animals; the combination's human efficacy is unproven, not disproven.
The bone-growth signal and the 2024 ferret data
The cleanest positive animal result is skeletal. Subcutaneous Ipamorelin at 18, 90, and 450 micrograms/day (divided three times daily for 15 days) raised longitudinal bone-growth rate in adult female rats from 42 micrometers/day on vehicle to 44, 50, and 52 micrometers/day — a tidy dose-response — with no change in total IGF-1, IGFBPs, or bone-turnover markers, implying a partly local, pulse-driven effect [4]. The most recent published in-vivo study, from 2024, used a ferret cachexia model: intraperitoneal Ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% in the delayed phase via a peripheral mechanism, though it produced no anti-emetic effect, in contrast to centrally administered anamorelin [5]. Together they sketch a peptide with real, measurable anabolic and weight-protective effects in animals.
Is ipamorelin fda approved
Is ipamorelin fda approved: no. Ipamorelin has never been approved by the FDA — or any regulatory authority — as a drug for any indication. It was investigated, most notably for postoperative ileus (NCT00672074), but that program ended after the Phase 2 trial in 114 bowel-resection patients missed its primary endpoint: time to first tolerated meal was 25.3 hours on Ipamorelin versus 32.6 hours on placebo (p=0.15) [3]. In 2024 the FDA removed Ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport under WADA category S2 [11].
The detection science
Because Ipamorelin is banned in sport, a substantial analytical literature exists purely to detect it. A comprehensive metabolism study identified at least three urinary metabolites of Ipamorelin — formed by exopeptidase, amidase, and endopeptidase activity — using UHPLC-Orbitrap mass spectrometry [8]. A high-throughput LC-MS/MS method with peptide derivatization detected Ipamorelin alongside seven other GHRPs in equine and human urine [9], and solid-phase extraction on 96-well microelution plates was validated for anti-doping screening using Ipamorelin and GHRP-6 metabolites as proof of concept [7]. Analytical work has also characterized GHRP metabolites in human urine after nasal administration, underpinning the detection methods accredited laboratories use [11]. The upshot: the compound is reliably detectable, which is what makes its prohibited-list status enforceable.